霍奇金淋巴瘤幸存者第二癌症风险及家族史的影响
基于瑞典家族癌症项目数据库纳入1965至2012年诊断的9522例原发霍奇金淋巴瘤患者,量化第二癌症风险并分析家族史影响。霍奇金淋巴瘤幸存者第二癌症总体风险升高2.39倍(95%CI 2.29至2.53);有癌症家族史者第二癌症风险更高,且肺癌家族史与霍奇金淋巴瘤治疗间存在超相加交互作用(P=.03)。
要点
- 霍奇金淋巴瘤幸存者第二癌症风险升高2.39倍(95%CI 2.29至2.53)。
- 35岁前诊断霍奇金淋巴瘤的女性30年乳腺癌累积发病率为13.8%。
- 一级亲属患癌者第二癌症风险升高1.3倍(P<.001)。
核心结论
- 霍奇金淋巴瘤幸存者存在实质性的第二癌症风险,有癌症家族史者风险更高。
- 该信息应被用于指导风险适应性治疗并辅助筛查,以降低霍奇金淋巴瘤患者的长期发病率与死亡率。
研究设计与样本
- 利用瑞典家族癌症项目数据库,识别1965年至2012年间诊断的原发霍奇金淋巴瘤患者9522例。
- 计算霍奇金淋巴瘤幸存者第二癌症的标准化发病比与累积发病率。
- 比较有与无特定部位癌症家族史的霍奇金淋巴瘤幸存者中肺癌、乳腺癌、结直肠癌及全部第二癌症的标准化发病比。
- 在相加模型与相乘模型下评估癌症家族史与霍奇金淋巴瘤治疗间的交互作用。
主要发现
- 霍奇金淋巴瘤幸存者第二癌症总体风险升高2.39倍(95%CI 2.29至2.53)。
- 35岁前诊断霍奇金淋巴瘤的女性30年乳腺癌累积发病率为13.8%。
- 未观察到相邻时间段间癌症风险有显著差异。
- 有一级亲属患癌的霍奇金淋巴瘤幸存者全部第二癌症风险升高1.3倍(P<.001)。
- 有一级亲属患癌的霍奇金淋巴瘤幸存者中,肺癌、结直肠癌、乳腺癌风险分别升高3.3倍、2.1倍、1.8倍。
临床怎么用
- 作者认为该信息应被用于指导风险适应性治疗并辅助筛查,以降低霍奇金淋巴瘤患者的长期发病率与死亡率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Although advances in Hodgkin lymphoma (HL) treatment have led to improved disease-free survival, this has been accompanied by an increased risk of second cancers. We sought to quantify the second cancer risks and to investigate the impact of family history. Patients and Methods Using the Swedish Family-Cancer Project Database, we identified 9,522 individuals with primary HL diagnosed between 1965 and 2012. We calculated standardized incidence ratios and cumulative incidence of second cancer in HL survivors and compared the standardized incidence ratios of lung, breast, colorectal, and all second cancers in HL survivors with and without a site-specific family history of cancer. Interactions between family history of cancer and HL treatment were evaluated under additive and multiplicative models. Results Overall, the risk of a second cancer in HL survivors was increased 2.39-fold (95% CI, 2.29 to 2.53). The 30-year cumulative incidence of breast cancer in women diagnosed with HL at younger than 35 years of age was 13.8%. We observed no significant difference in cancer risk over successive time periods. The risk of all second cancers was 1.3-fold higher for HL survivors with a first-degree relative with cancer ( P < .001), with 3.3-fold, 2.1-fold, and 1.8-fold differences shown for lung, colorectal, and breast cancers, respectively. Moreover, a greater than additive interaction between family history of lung cancer and HL treatment was shown ( P = .03). Conclusion HL survivorship is associated with a substantive risk of a second cancer. Notably, the risk is higher in individuals with a family history of cancer. This information should be used to inform risk-adapted therapy and to assist in screening to reduce long-term morbidity and mortality in patients with HL.
引用
- Sud A, Thomsen H, Sundquist K, et al. Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History. J Clin Oncol. 2017. PMID: 28384078. doi:10.1200/JCO.2016.70.9709
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。